Related Experiment Video
Updated: Mar 15, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells
Shufeng Zhang1, Xiaohui Wang1, Zhimin Gu2
1a Department of Pediatric Surgery , People's Hospital of Zhengzhou University , Zhengzhou , China.
Abstract:
Survivin is an important oncogenic protein expressed highly in osteosarcoma. Here, we have shown that small molecule inhibitor YM155 potently suppressed survivin expression, inhibited cell growth, and induced apoptosis in osteosarcoma cells. Furthermore, we also showed that knock down of survivin by small interfering RNA strongly inhibited cell viability in two osteosarcoma cell lines, suggesting that suppression of survivin essentially contributes to YM155-mediated anticancer activity in osteosarcoma cells. Collectively, our study suggests that YM155 holds promise for patients with osteosarcoma.
Insights
The small molecule inhibitor YM155 effectively suppresses survivin, a key protein in osteosarcoma. This suppression halts cancer cell growth and triggers cell death, indicating YM155
Area of Science:
- Oncology
- Molecular Biology
Background:
- Survivin is a crucial oncogenic protein frequently overexpressed in osteosarcoma.
- Targeting survivin presents a potential therapeutic strategy for osteosarcoma.
Purpose of the Study:
- To investigate the efficacy of the small molecule inhibitor YM155 in targeting survivin in osteosarcoma.
- To evaluate the impact of YM155 on osteosarcoma cell growth, apoptosis, and survivin expression.
Main Methods:
- Treatment of osteosarcoma cells with YM155.
- Knockdown of survivin using small interfering RNA (siRNA).
- Assessment of cell viability, growth inhibition, and apoptosis induction.
Main Results:
- YM155 significantly suppressed survivin expression in osteosarcoma cells.
- YM155 inhibited osteosarcoma cell growth and induced apoptosis.
- Survivin knockdown via siRNA also strongly inhibited cell viability, confirming its role in YM155's effects.
Conclusions:
- Survivin suppression is critical for the anticancer activity of YM155 in osteosarcoma.
- YM155 demonstrates significant therapeutic potential for osteosarcoma treatment.
- Further investigation of YM155 as a treatment for osteosarcoma patients is warranted.
